Results 101 to 110 of about 9,419,823 (304)

How structural disorder and polyelectrolyte properties of prothymosin α enable its large interactome

open access: yesFEBS Letters, EarlyView.
In this review, complexes of the fully disordered and highly negatively charged prothymosin α are collected, described, and discussed. Linked to its poly‐electrostatic character, prothymosin α engages a large interactome through multiple different binding modes ranging from fully disordered complexes to short linear motif (SLiM)‐driven interactions ...
Ketty C. Tamburrini   +3 more
wiley   +1 more source

The Impact on Systematic Reviews of Risk of Bias Assessment Changes From Conference Abstracts to Full Text

open access: yesCochrane Evidence Synthesis and Methods
Conference abstracts are commonly included in systematic reviews of evidence. Due to limitations in word count, conference abstracts often lack data or information. This causes issues for the assessment of risk of bias (RoB).
Ryan P. W. Kenny   +4 more
doaj   +1 more source

Wavelets for intonation modeling in HMM speech synthesis [PDF]

open access: yes, 2013
The pitch contour in speech contains information about different linguistic units at several distinct temporal scales. At the finest level, the microprosodic cues are purely segmental in nature, whereas in the coarser time scales, lexical tones, word ...
Suni, Antti Santeri   +5 more
core  

Tumour–host interactions in Drosophila: mechanisms in the tumour micro‐ and macroenvironment

open access: yesMolecular Oncology, EarlyView.
This review examines how tumour–host crosstalk takes place at multiple levels of biological organisation, from local cell competition and immune crosstalk to organism‐wide metabolic and physiological collapse. Here, we integrate findings from Drosophila melanogaster studies that reveal conserved mechanisms through which tumours hijack host systems to ...
José Teles‐Reis, Tor Erik Rusten
wiley   +1 more source

2024 Evidence Synthesis Institute Conference Abstracts

open access: yes
The 2024 ESI Conference Planning Committee included the following people: Megan Kocher from University of Minnesota (PI), Amy Riegelman from University of Minnesota (Co-PI), Sarah Young from Carnegie Mellon University, Scott Marsalis from University of ...
Evidence Synthesis Institute
core  

Developmental programmes drive cellular plasticity, disease progression and therapy resistance in lung adenocarcinoma

open access: yesMolecular Oncology, EarlyView.
This study shows that lung adenocarcinomas exploit developmental branching morphogenesis to acquire a therapy resistant basal‐like tumour cell state. This process was found to be regulated by combined TP53 loss‐of‐function and type‐I interferon signalling, identifying a novel axis for biomarker and therapeutic target discovery.
Kamila J Bienkowska   +13 more
wiley   +1 more source

The Promise of Evidence-Based Policymaking: Report of the Commission on Evidence-Based Policymaking, Appendices E-H

open access: yes, 2017
Final report appendices E-H of the Commission on Evidence-Based Policymaking (CEP) containing the information gathered through the commission's survey of federal offices, public meeting materials and presentations, public input-hearing testimony and ...
United States. Commission on Evidence-Based Policymaking
core  

Circulating microRNA signatures of cachexia and cancer in Canis familiaris as a comparative oncology model for human disease

open access: yesMolecular Oncology, EarlyView.
Circulating microRNAs as biomarkers of cachexia and sex‐specific cancer in senior dogs. In 25 client‐owned dogs, four circulating miRNAs (miR‐15a, miR‐15b, miR‐16, miR‐140) were downregulated in cachexia, with miR‐16 the strongest individual biomarker (AUC = 0.899).
Soon‐Seok Park   +6 more
wiley   +1 more source

The Promise of Evidence-Based Policymaking, Final Report and Appendices A-D

open access: yes, 2017
Final report of the Commission on Evidence-Based Policymaking (CEP) describing their activities and findings regarding evidence access, privacy protections, accountability, and building capacity.
United States. Commission on Evidence-Based Policymaking
core  

Somatostatin receptor 4 (SSTR4) is a tumor suppressor in cutaneous and head & neck squamous cell carcinomas

open access: yesMolecular Oncology, EarlyView.
This study identifies somatostatin receptor 4 (Sstr4) as a critical tumor suppressor against skin and head/neck cancers (HNSCC, cSCC, and BCC). The loss of Sstr4 removes a check on cell growth, causing hyperactivation of the MAPK‐ERK signaling pathway (↑).
Ali Taqvi   +6 more
wiley   +1 more source

Home - About - Disclaimer - Privacy